Ming Yan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11036969/publications.pdf Version: 2024-02-01



MINC YAN

#	Article	IF	CITATIONS
1	Protein ISGylation modulates the JAK-STAT signaling pathway. Genes and Development, 2003, 17, 455-460.	5.9	276
2	Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nature Medicine, 2004, 10, 1374-1378.	30.7	245
3	A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nature Medicine, 2006, 12, 945-949.	30.7	244
4	Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood, 2007, 109, 3441-3450.	1.4	182
5	Alpha Interferon Induces Long-Lasting Refractoriness of JAK-STAT Signaling in the Mouse Liver through Induction of USP18/UBP43. Molecular and Cellular Biology, 2009, 29, 4841-4851.	2.3	160
6	STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling. Nature Structural and Molecular Biology, 2017, 24, 279-289.	8.2	140
7	Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17186-17191.	7.1	113
8	Ube1L and Protein ISGylation Are Not Essential for Alpha/Beta Interferon Signaling. Molecular and Cellular Biology, 2006, 26, 472-479.	2.3	113
9	RUNX1a enhances hematopoietic lineage commitment from human embryonic stem cells and inducible pluripotent stem cells. Blood, 2013, 121, 2882-2890.	1.4	111
10	PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential. Blood, 2012, 119, 4953-4962.	1.4	106
11	Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood, 2007, 110, 799-805.	1.4	105
12	SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing. Molecular and Cellular Biology, 2015, 35, 3071-3082.	2.3	92
13	USP18 inhibits NF-κB and NFAT activation during Th17 differentiation by deubiquitinating the TAK1–TAB1 complex. Journal of Experimental Medicine, 2013, 210, 1575-1590.	8.5	89
14	Enhanced Antibacterial Potential in UBP43-Deficient Mice against <i>Salmonella typhimurium</i> Infection by Up-Regulating Type I IFN Signaling. Journal of Immunology, 2005, 175, 847-854.	0.8	88
15	Identification and characterization of a novel ISG15-ubiquitin mixed chain and its role in regulating protein homeostasis. Scientific Reports, 2015, 5, 12704.	3.3	76
16	The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. Blood, 2007, 109, 4392-4398.	1.4	57
17	Microarray analysis reveals that Type I interferon strongly increases the expression of immune-response related genes in Ubp43 (Usp18) deficient macrophages. Biochemical and Biophysical Research Communications, 2007, 356, 193-199.	2.1	49
18	Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling. Blood, 2007, 110, 305-312.	1.4	45

Ming Yan

#	Article	IF	CITATIONS
19	RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis. Blood, 2009, 113, 883-886.	1.4	44
20	Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17103-17108.	7.1	43
21	Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14313-14318.	7.1	41
22	Runx1 exon 6–related alternative splicing isoforms differentially regulate hematopoiesis in mice. Blood, 2014, 123, 3760-3769.	1.4	37
23	Plakophilin-2 Promotes Tumor Development by Enhancing Ligand-Dependent and -Independent Epidermal Growth Factor Receptor Dimerization and Activation. Molecular and Cellular Biology, 2014, 34, 3843-3854.	2.3	34
24	A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy. Blood, 2007, 109, 3963-3971.	1.4	31
25	SON Protein Regulates GATA-2 through Transcriptional Control of the MicroRNA 23aâ^1/427aâ^1/424-2 Cluster*. Journal of Biological Chemistry, 2013, 288, 5381-5388.	3.4	31
26	Alteration of tumor spectrum by ISGylation in p53-deficient mice. Cancer Biology and Therapy, 2009, 8, 1167-1172.	3.4	26
27	Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML. Blood, 2012, 120, 1473-1484.	1.4	25
28	Cooperation between RUNX1-ETO9a and Novel Transcriptional Partner KLF6 in Upregulation of Alox5 in Acute Myeloid Leukemia. PLoS Genetics, 2013, 9, e1003765.	3.5	22
29	Ubp43 gene expression is required for normal Isg15 expression and fetal development. Reproductive Biology and Endocrinology, 2007, 5, 13.	3.3	21
30	Usp18 Promotes Conventional CD11b+ Dendritic Cell Development. Journal of Immunology, 2012, 188, 4776-4781.	0.8	20
31	Negative effects of GM-CSF signaling in a murine model of t(8;21)–induced leukemia. Blood, 2012, 119, 3155-3163.	1.4	20
32	Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential. Blood, 2013, 121, 3714-3717.	1.4	18
33	Murine Herc6 Plays a Critical Role in Protein ISGylation <i>In Vivo</i> and Has an ISGylation-Independent Function in Seminal Vesicles. Journal of Interferon and Cytokine Research, 2015, 35, 351-358.	1.2	16
34	Persistent altered fusion transcript splicing identifies <i>RUNX1â€RUNX1T1</i> + AML patients likely to relapse. European Journal of Haematology, 2010, 84, 128-132.	2.2	13
35	Deficiency of a potential 3p21.3 tumor suppressor gene UBE1L (UBA7) does not accelerate lung cancer development in K-rasLA2 mice. Lung Cancer, 2009, 63, 194-200.	2.0	11
36	Hematopoietic cells from Ube1L-deficient mice exhibit an impaired proliferation defect under the stress of bone marrow transplantation. Blood Cells, Molecules, and Diseases, 2010, 45, 103-111.	1.4	11

Ming Yan

#	Article	IF	CITATIONS
37	RUNX1–ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development. Leukemia and Lymphoma, 2014, 55, 884-891.	1.3	11
38	The RUNX1-ETO target gene RASSF2 suppresses t(8;21) AML development and regulates Rac GTPase signaling. Blood Cancer Journal, 2020, 10, 16.	6.2	8
39	AML1-ETO9a, an Alternatively Spliced Form of AML1-ETO, Collaborates with AML1-ETO To Promote Leukemogenesis Blood, 2005, 106, 661-661.	1.4	2
40	Response: the role of RUNX1 isoforms in hematopoietic commitment of human pluripotent stem cells. Blood, 2013, 121, 5252-5253.	1.4	0
41	The Dimerization Domain and C-Terminal NCoR/SMRT Interacting Zinc-Finger Domain of t(8;21) Fusion Protein AML1-ETO Have Critical and Opposite Effects on Leukemogenesis Blood, 2004, 104, 2556-2556.	1.4	0
42	Differential Effects on Cell Cycle Regulators by AML1-ETO and a C-Terminal Truncated AML1-ETO (From) Tj ETQq	0 0 0 rgBT 1.4	Overlock 10